Brokerages expect that Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) will report ($0.43) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Indaptus Therapeutics’ earnings. Indaptus Therapeutics posted earnings of ($5.53) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 92.2%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Indaptus Therapeutics will report full year earnings of ($2.15) per share for the current financial year, with EPS estimates ranging from ($2.45) to ($1.85). For the next fiscal year, analysts forecast that the company will report earnings of ($2.74) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Indaptus Therapeutics.
Several analysts recently commented on INDP shares. Zacks Investment Research raised Indaptus Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, April 5th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Indaptus Therapeutics in a report on Monday, January 31st.
A number of institutional investors and hedge funds have recently modified their holdings of INDP. Stratos Wealth Partners LTD. acquired a new stake in Indaptus Therapeutics in the fourth quarter valued at approximately $7,914,000. Investment House LLC grew its holdings in Indaptus Therapeutics by 272.8% in the fourth quarter. Investment House LLC now owns 95,629 shares of the company’s stock valued at $545,000 after purchasing an additional 69,976 shares during the period. Geode Capital Management LLC grew its holdings in Indaptus Therapeutics by 213.0% in the fourth quarter. Geode Capital Management LLC now owns 85,914 shares of the company’s stock valued at $489,000 after purchasing an additional 58,464 shares during the period. Vanguard Group Inc. grew its holdings in Indaptus Therapeutics by 18.7% in the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock valued at $969,000 after purchasing an additional 38,216 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Indaptus Therapeutics in the fourth quarter worth approximately $217,000. 22.26% of the stock is currently owned by institutional investors.
Indaptus Therapeutics Company Profile (Get Rating)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.